You are here

  • Home
  • Archive
  • Volume 78, Issue 7
  • Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

Article metrics

Article menu
XML
Rheumatoid arthritis
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

 

Online download statistics by month:

Online download statistics by month: April 2019 to March 2024

AbstractFullPdf
Apr 2019757720
May 201917261756537
Jun 201910411024255
Jul 2019515502177
Aug 2019204195102
Sep 201918117982
Oct 201919919087
Nov 201915415278
Dec 201910510248
Jan 202011711748
Feb 2020898852
Mar 202012312255
Apr 2020868579
May 202010610659
Jun 2020686834
Jul 2020727242
Aug 202011310352
Sep 202033228661
Oct 202018816776
Nov 202011710960
Dec 2020786321
Jan 2021575335
Feb 2021606138
Mar 2021747445
Apr 2021575838
May 2021535338
Jun 2021615830
Jul 2021464524
Aug 2021373227
Sep 2021615722
Oct 2021645648
Nov 2021575645
Dec 2021646438
Jan 2022575527
Feb 2022787728
Mar 202210610442
Apr 2022616334
May 2022565714
Jun 2022555416
Jul 2022444324
Aug 2022585719
Sep 2022828036
Oct 2022686319
Nov 2022494826
Dec 2022333118
Jan 2023252311
Feb 2023565316
Mar 2023282619
Apr 2023312913
May 2023282220
Jun 202333318
Jul 2023414013
Aug 2023565420
Sep 202346448
Oct 2023807814
Nov 2023675617
Dec 2023524522
Jan 2024737118
Feb 2024929321
Mar 2024878525
Total792277123001